Emerald Mutual Fund Advisers Trust Grows Position in Cogent Biosciences, Inc. $COGT

Emerald Mutual Fund Advisers Trust raised its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) by 14.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,022,858 shares of the technology company’s stock after purchasing an additional 127,446 shares during the period. Emerald Mutual Fund Advisers Trust owned 0.90% of Cogent Biosciences worth $14,688,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Osaic Holdings Inc. lifted its position in shares of Cogent Biosciences by 41.4% during the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock valued at $33,000 after buying an additional 1,333 shares in the last quarter. Strs Ohio bought a new stake in Cogent Biosciences during the 1st quarter worth approximately $36,000. Ameritas Investment Partners Inc. lifted its holdings in Cogent Biosciences by 16.6% during the second quarter. Ameritas Investment Partners Inc. now owns 10,839 shares of the technology company’s stock valued at $78,000 after purchasing an additional 1,543 shares in the last quarter. CWM LLC boosted its position in shares of Cogent Biosciences by 25.3% in the third quarter. CWM LLC now owns 5,582 shares of the technology company’s stock worth $80,000 after purchasing an additional 1,126 shares during the period. Finally, Prudential Financial Inc. purchased a new stake in shares of Cogent Biosciences in the second quarter worth $93,000.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HC Wainwright upped their target price on shares of Cogent Biosciences to $52.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen raised Cogent Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Leerink Partners lifted their target price on Cogent Biosciences from $18.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, November 10th. Robert W. Baird boosted their price target on Cogent Biosciences from $14.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Finally, UBS Group upgraded Cogent Biosciences to a “strong-buy” rating in a research note on Wednesday, January 7th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $39.55.

Insider Buying and Selling at Cogent Biosciences

In other Cogent Biosciences news, insider Jessica Sachs sold 82,642 shares of the stock in a transaction on Friday, December 26th. The shares were sold at an average price of $38.70, for a total transaction of $3,198,245.40. Following the completion of the transaction, the insider owned 133,938 shares in the company, valued at $5,183,400.60. This trade represents a 38.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Evan Kearns sold 65,000 shares of Cogent Biosciences stock in a transaction on Friday, December 26th. The stock was sold at an average price of $38.70, for a total transaction of $2,515,500.00. Following the completion of the transaction, the insider directly owned 109,398 shares of the company’s stock, valued at $4,233,702.60. The trade was a 37.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,737,642 shares of company stock valued at $136,600,345. 7.29% of the stock is owned by company insiders.

Cogent Biosciences Price Performance

NASDAQ:COGT opened at $39.53 on Friday. The business’s 50-day moving average is $37.99 and its 200 day moving average is $22.35. Cogent Biosciences, Inc. has a 12 month low of $3.72 and a 12 month high of $43.73. The company has a market capitalization of $5.63 billion, a P/E ratio of -24.10 and a beta of 0.50. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.23.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings results on Monday, November 3rd. The technology company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.04. On average, equities research analysts forecast that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current fiscal year.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.